VALEANT PHARMACEUTICALS INTL VRX.
May 12, 2017 - 3:59pm EST by
member
2017 2018
Price: 13.66 EPS 6.0 0
Shares Out. (in M): 341 P/E 2.3 0
Market Cap (in $M): 4,800 P/FCF 2.61 0
Net Debt (in $M): 0 EBIT 0 0
TEV (in $M): 32,141 TEV/EBIT TEV / EBITDA: 10X 0

Description

    show   sort by    
You are not eligible to view 15 messages. To gain access to more recent message posts signup free for membership.
  53
member
6/01/22
Fraudulent Transfer Action analysis/comments
 
  52
member
5/27/22
Re: Re: Re: Re: Re: Garbitrage
51    
  50
member
5/26/22
Re: Re: Re: Garbitrage
49    
  49
member
5/25/22
Re: Re: Garbitrage
48    
  48
member
5/25/22
Re: Garbitrage
47    
  47
member
5/25/22
Garbitrage
 
  46
member
2/11/21
ICAHN
 
  45
member
10/16/19
Citron Research piece (I guess if he says it, it is true)
 
  44
member
6/06/18
If it holds 25 it will be a terrific stock for the rest of the year barring a market wide calamity.
 
  43
member
12/10/17
Not only was there no dilutive debt for equity swap; there are billions of dollars of access to cred
 
  42
member
6/28/17
VRX equity swap rumblings...From ISI
 
  40
member
6/26/17
Re: Re: Re: Re: Re: And now? Plenty of time to still buy!
39    
  39
member
6/26/17
Re: Re: Re: Re: And now? Plenty of time to still buy!
38    
  38
member
6/26/17
Re: Re: Re: And now? Plenty of time to still buy!
37    
  36
member
6/26/17
Re: And now? Plenty of time to still buy!
34    
  34
member
6/26/17
And now? Plenty of time to still buy!
 
  33
member
5/15/17
Re: why not...
32    
  32
member
5/15/17
why not...
31    
  31
member
5/15/17
Re: Re: Re: Some thoughts
29    
  30
member
5/15/17
Taking the discussion further
 
  28
member
5/14/17
Re: Some thoughts
16    
  25
member
5/14/17
Re: Re: Thank you
22    
  24
member
5/14/17
Re: Re: Re: Re: Some thoughts
20    
  22
member
5/14/17
Re: Thank you
21    
  20
member
5/14/17
Re: Re: Re: Some thoughts
19    
  19
member
5/14/17
Re: Re: Some thoughts
17    
  18
member
5/14/17
Re: Some thoughts
16    
  17
member
5/14/17
Re: Some thoughts
16    
  15
member
5/14/17
Re: Re: More commentary.
14    
  14
member
5/13/17
Re: More commentary.
13    
  Back to top